Did the Wegovy price go up — and what does that mean for you?

The biggest misconception: the price listed is the price you pay

A lot of people assume the figure shown on a provider's website is all they'll hand over. That turns out to be wrong surprisingly often. In the private weight-loss market, headline prices frequently don't include the consultation fee, the prescription charge, or delivery. Some providers charge separately for each dose increase review. Others bundle a starting price that only applies to the lowest strength, then the cost climbs once you titrate up. It's not necessarily dishonest (it reflects genuine variation in how services are structured) but it means comparing a £149 headline from one provider with a £250 headline from another is often comparing apples with something quite different.

Wegovy (semaglutide, made by Novo Nordisk) is licensed in the UK for weight management in adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition. It's a prescription-only medicine, which means a qualified prescriber must assess you before any supply is lawful. That assessment has a cost, even when it's absorbed into a single price, it's there. When you see a price that looks strikingly low, the honest question to ask is what's not in it. You can explore what Wegovy typically costs in the UK and what goes into those figures.

What actually happened to Wegovy prices since 2025

The UK private market for semaglutide has shifted noticeably, and if you're wondering whether Wegovy did go down in price, the answer is more complicated than a simple yes or no. Reported private prices since that period range roughly £149 to £375 per month depending on the dose and the provider, though those figures carry the usual caveats: prices change, providers differ, and a per-month figure at the starting 0.25mg dose looks very different from the same figure at the 2.4mg maintenance dose. If you want a fuller picture of where prices sit right now, our guide to 2.4mg Wegovy pricing sets out the market context clearly.

There's also a broader question of whether prices will keep moving. Supply stabilised through 2025 into 2026, which helped, but demand for GLP-1 medicines in the UK remains high. The NICE recommendation for semaglutide under TA875 covers NHS access through specialist services, but NHS waiting lists remain long in most areas, which keeps private demand elevated, and private prices with it. For a longer look at where things might go, the outlook for Wegovy pricing is worth reading alongside the question of whether Wegovy's price is going up in the near term.

What a single transparent price should actually include

At nume, we made a deliberate decision not to compete on headline price. That's not an accident. We cover the consultation, the prescription, the medicine, and tracked next-day delivery in a single figure, no separate fees at any stage, no subscription quietly auto-renewing, no charge to ask a clinical question. A real clinician reads your consultation the same day; our clinical team reviews every repeat before it goes out. Before every dose increase, you provide evidence your current dose is working. That infrastructure has a cost, and we'd rather you know that plainly than discover what's missing somewhere cheaper.

We lose the price-comparison table on purpose. If what you need is the lowest possible number attached to a semaglutide pen, we're not going to win that race, and we're not trying to. What we can offer is a clinical service where the thing that varies isn't the quality of your care. A bit more about how we work sets out the thinking behind that.

Why 'cheapest' is the wrong test for a prescription medicine

There's a reason the MHRA has warned repeatedly about fake weight-loss pens sold online, some containing insulin rather than semaglutide, some with no active ingredient at all. In October 2023 the first major public warning came after counterfeit semaglutide pens were seized across the UK, with some hospitalisations recorded. The pattern has continued. A price far below the reported market rate, with no verifiable prescription process, is a red flag, not a bargain.

The right test for any online pharmacy is whether you can verify it. The GPhC publishes a public register at pharmacyregulation.org/registers, check any provider before you share your health information, let alone receive a medicine. Suspect sellers can be reported via the MHRA's Yellow Card scheme, which also covers side-effect reporting. For Wegovy specifically, people often ask how much weight others have lost on Wegovy before committing, and starting with a free consultation is how you find out whether you're clinically suitable, and that assessment is worth more than any saving on the pen itself.